MedTrace Logo

Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome

NCT00003827 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2013-12-04

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.

PURPOSE: Phase II trial to study the effectiveness of combining topotecan and cytarabine given with amifostine in treating patients who have myelodysplastic syndrome.

Conditions

Interventions

DRUG

amifostine trihydrate

DRUG

cytarabine

DRUG

topotecan hydrochloride

Sponsors & Collaborators

  • ALZA

    lead INDUSTRY

Principal Investigators

  • Henry C. Fung, MD, FRCPE · City of Hope Comprehensive Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003827 on ClinicalTrials.gov